Innovation | Novartis United States of America

Media Release
Dec 12, 2011
Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
Media Release
Nov 07, 2011
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
Media Release
Apr 03, 2012
Novartis expands transplant portfolio with Hecoria®, the first generic tacrolimus that can be prescribed by brand name
Media Release
Mar 19, 2012
Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
Media Release
Jan 25, 2012
Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
Media Release
Apr 26, 2012
Higher dose of Novartis drug Exelon® Patch showed statistically significantly less decline in function in Alzheimer’s vs. lower dose
Media Release
Apr 24, 2012
New extension study data with Novartis drug Gilenya shows patients successfully treated for up to 7 years in relapsing MS
Media Release
Apr 20, 2012
Novartis announces update to United States prescribing information for MS therapy Gilenya following FDA review
Media Release
Jun 06, 2012
NPC Statement on Comments Made in Media Coverage of Paycheck Fairness Act
Media Release
May 31, 2012
Two new analyses reinforce consistent efficacy of Novartis therapy Gilenya across wide range of relapsing MS patients
Media Release
May 08, 2012
TV host Phil Keoghan and professional women cyclists join Novartis to raise awareness of multiple sclerosis
Media Release
Sep 26, 2012
Novartis Pharmaceuticals Corporation embarks on Alzheimer’s disease educational effort for the U.S. Hispanic community

‹ Previous page
1
…
30
31
32
33
34
35
36
…
50
› Next page